Navigation Links
JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
Date:3/7/2008

UPPSALA, Sweden and WILMINGTON, Mass., March 7 /PRNewswire/ -- The Journal of the American College of Cardiology has recognized the five-year follow-up results of the DEFER (Deferral Versus Performance of PTCA in Patients Without Documented Ischemia) as one of the studies that had the greatest impact on cardiology in 2007, according to an article entitled "Highlights of the Year in JACC" by Anthony N. DeMaria, MD, et al. (JACC Vol. 51, No. 4, 2008 January 29, 2008:490-512)

Initially published in the May 29, 2007, issue of the peer-reviewed journal, DEFER concluded that patients treated based on fractional flow reserve (FFR) results had achieved long-term outcomes equal, or superior, to patients who underwent stenting solely based on angiographic evidence. The study's investigators measured FFR using PressureWire(R), a diagnostic tool developed by Radi Medical Systems AB.

Dr. Nico Pijls, the study's principal investigator, said, "From the DEFER study and other recent publications, it has become clear that the key issue in deciding which lesions should be stented is knowledge about whether a stenosis is responsible for ischemia. We are glad that JACC has recognized this study that demonstrates the importance of FFR and its role in interventional cardiology."

FFR expresses maximum achievable blood flow in a coronary artery with abnormal stenosis as a fraction of maximum blood flow in the absence of a stenosis. FFR is 100% specific in identifying which lesions are actually causing the flow restriction and may be treated.

"The DEFER data was, and continues to be, an important topic of discussion among cardiologists," said Jim Archetto, Chief Operating Officer of Radi Medical Systems, Inc. "There is a lot of uncertainty in interventional cardiology when it comes to determining whether or not a stent is necessary. Measuring FFR is the only way physicians can determine with precision that a suspect lesion requires treatment."

As an adjunct to DEFER, authors have designed a new 1000 patient study, Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) (American Heart Journal Volume 154, Number 4). The objective of this groundbreaking, multicenter, randomized clinical trial is to compare angiographic guidance versus fractional flow reserve (FFR) to determine which coronary lesions to stent in patients with multivessel coronary disease.

The primary end point of the study is a composite of major adverse cardiac events, including death, myocardial infarction, and repeat coronary revascularization, at 1 year.

About Radi Medical Systems AB

Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 350 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit http://www.radi.se.

Media Contacts:

David Schull or Ian Stone

Russo Partners LLC

+1 212-845-4271

david.schull@russopartnersllc.com

ian.stone@russopartnersllc.com

Jim Archetto

Radi Medical Systems Inc.

+1 877-337-7234 x812

jim.archetto@radi.se


'/>"/>
SOURCE Radi Medical Systems AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
3. Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood
4. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
5. St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory
6. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017 Sherpa Clinical Packaging ( www.sherpaclinical.com ... is pleased to announce the appointment of Kevin Rosenthal as ... Sherpa team to lead Sherpa,s Operations group and ... excellence. Kevin is not new to ... He has extensive experience working for leading pharma ...
(Date:1/24/2017)... YORK , January 24, 2017 ... the fastest growing industries in the United States ... medicinal use in 2016. In addition, Proposition 64, the California ... for and 42.87% against on November 8, 2016. This outcome ... allowed to use and to grow a certain amount of ...
(Date:1/24/2017)... 24, 2017   Keneric Healthcare , a ... effective patient care products, today announced their partnership ... the reach of both companies by leveraging their ... Angelini Pharma Inc . ... include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal).  RTD™ ...
Breaking Medicine Technology:
(Date:1/24/2017)... Houston, TEXAS (PRWEB) , ... January 24, 2017 ... ... firm and solution provider of enterprise software products, today announced a strategic partnership ... enable Element Blue users to access and analyze their Fusion platform for building ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... was recently accepted as a Registered Trademark by the United States Patent and ... a similar name which could confuse consumers into thinking that other products are ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups have been ... 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO Kevin ... will showcase their businesses on February 6, 2017, at Under Armour’s global headquarters ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... it has officially formed a distribution partnership with Byers Scientific & Manufacturing ... management industry. , Through the agreement, OMI Industries formulated a special version of ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Center for ... century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... - as its Hispanic Leader of the Month. City of Hope is committed to ...
Breaking Medicine News(10 mins):